Olgu Sunumu
BibTex RIS Kaynak Göster

Severe tumor lysis syndrome after rituximab-bendamustine in nodal marginal zone lymphoma

Yıl 2022, , 674 - 676, 12.12.2022
https://doi.org/10.19161/etd.1208981

Öz

Marginal zone lymphomas are the third most common subtype of Non-Hodgkin lymphomas. Nodal marginal zone lymphoma is one of the subtypes of marginal zone lymphoma. It usually occurs after the sixth decade. It is a B-cell lymphoma with an incidence of approximately 1% among all lymphomas. Tumor lysis syndrome (TLS) is rarely seen in the treatment of nodal marginal zone lymphoma. At the same time, TLS is not an expectation in rituximab-bendamustine chemotherapy. Our case presented to our clinic with complaints of nausea and vomiting after rituximab-bendamustine chemotherapy treatment in a patient with a diagnosis of nodal marginal zone lymphoma, and TLS was detected. As a result, the possibility of TLS should be considered when patients present with a giant mass and high LDH level, especially with acute kidney injury, even if they have low-grade lymphoma

Kaynakça

  • Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.
  • Çetinkaya R., Yılmaz V. T. Tümör Lizis Sendromu. Turkiye Klinikleri J Nephrol-Special Topics. 2014;7(1):74-7.
  • Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med 2008;3:161–63.
  • Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89 –91.
  • Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–50.
  • Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946 – 48.
  • Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337-41. doi:10.1097/MAJ.0b013e318244db6f
  • Naithani R, Bhat A, Bhasin A. Bendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia. Indian J Cancer. 2014;51(3):380-1. doi:10.4103/0019-509X.146740
  • Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-66. doi:10.1200/JCO.2010.33.8061
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013 Apr 6;381(9873):1184]. Lancet. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2

Nodal marjinal zon lenfomada rituksimab-bendamustin sonrası ağır tümör lizis sendromu

Yıl 2022, , 674 - 676, 12.12.2022
https://doi.org/10.19161/etd.1208981

Öz

Marjinal zon lenfomalar, Hodgkin dışı lenfomalar arasında en sık görülen üçüncü alt tiptir. Nodal marjinal zon lenfoma, marjinal zon lenfomanın alt tiplerinden biridir. Genellikle altıncı dekattan sonra ortaya çıkar. Tüm lenfomalar içinde yaklaşık %1 görülme oranına sahip, B hücreli bir lenfomadır. Nodal marjinal zon lenfoma tedavisinde, tümör lizis sendromu (TLS) nadir görülmektedir. Aynı zamanda herhangi bir nedenle rituksimab-bendamustin kemoterapisinde de TLS beklenti değildir. Olgumuz, nodal marjinal zon lenfoma tanılı hastada rituximab-bendamustin kemoterapi tedavisi sonrası bulantı ve kusma şikayetleri ile kliniğimize başvurmuş olup TLS saptanmıştır. Sonuç olarak hastalar düşük dereceli lenfoma bile olsa dev kitlesi ve LDH yüksekliğinde özellikle akut böbrek hasarı tablosu ile başvurduğunda TLS olasılığı göz önünde bulundurulmalıdır.

Kaynakça

  • Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.
  • Çetinkaya R., Yılmaz V. T. Tümör Lizis Sendromu. Turkiye Klinikleri J Nephrol-Special Topics. 2014;7(1):74-7.
  • Otrock ZK, Hatoum HA, Salem ZM. Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma. Intern Emerg Med 2008;3:161–63.
  • Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89 –91.
  • Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–50.
  • Francescone SA, Murphy B, Fallon JT, et al. Tumor lysis syndrome occurring after the administration of rituximab for posttransplant lymphoproliferative disorder. Transplant Proc 2009;41:1946 – 48.
  • Yang B, Lu XC, Yu RL, et al. Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma. Am J Med Sci. 2012;343(4):337-41. doi:10.1097/MAJ.0b013e318244db6f
  • Naithani R, Bhat A, Bhasin A. Bendamustine induced tumor lysis syndrome with acute renal failure in chronic lymphocytic leukemia. Indian J Cancer. 2014;51(3):380-1. doi:10.4103/0019-509X.146740
  • Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-66. doi:10.1200/JCO.2010.33.8061
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [published correction appears in Lancet. 2013 Apr 6;381(9873):1184]. Lancet. 2013;381(9873):1203-1210. doi:10.1016/S0140-6736(12)61763-2
Toplam 10 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Kurumları Yönetimi
Bölüm Olgu Sunumu
Yazarlar

Gökhan Çolak

İrfan Yavaşoğlu

Yayımlanma Tarihi 12 Aralık 2022
Gönderilme Tarihi 5 Şubat 2022
Yayımlandığı Sayı Yıl 2022

Kaynak Göster

Vancouver Çolak G, Yavaşoğlu İ. Nodal marjinal zon lenfomada rituksimab-bendamustin sonrası ağır tümör lizis sendromu. ETD. 2022;61(4):674-6.

1724617243172472652917240      26515    

 26507    26508 26517265142651826513

2652026519